The Health&BioTech Accelerator is a pilot-driven & business-oriented international program. It aims to develop industrial projects between forward-thinking startups/scaleups and leading corporations by matching both the corporate and startup business objectives.

The program is 15 weeks long. It begins at the beginning of April and ends with a demo day in July. Corporates and startups may decide to continue the pilot after the July date and/or to negotiate further possibilities for interaction such as commercial agreements, co-development agreements, investments or acquisitions.

No, there is no equity or need for payment to the program to participate. The corporate partners may want to invest and agree to the terms prior to the program.

If you want to work on actual industrial pilots, test your solution’sreadiness level by working with an industrial or clinical partner, get your clinical trial started, build your regulatory strategy, gain more traction or enter a new market, this is the right program for you. The Health&BioTech Accelerator is a radical opportunity to push your venture forward with the help of committed corporates that are ready to share their capabilities to drive innovation and experienced mentors to facilitate each project.

No, there is no need to relocate for the entire program. We try to be as founder friendly as possible though we do require (in compliance with all Covid-19 regulations) participation for our launch, demo day and depending on your pilot, for one or more members of your team to attend any meetings/labs/activities in order to ensure the project’s success.

No, we do not reimburse or pay for any travel expenses.

This is not a traditional accelerator. Being a corporate scale-up program it’s not about how good your solution is but more about how good of a fit it is with our Corporate Partners’ innovation needs. Please refer to the “Who Should Apply” section for more information. We do look for a great, flexible and collaborative team that is motivated and ready to work with an industrial or clinical partner.

Not necessarily, if your company is developing breakthrough innovative solutions to make patients’ lives better, safeguard people’s health or make healthcare systems more efficient, you should definitely apply and select the macro-trend that you feel is closes to what you do.

Absolutely! We welcome you to do so.

We like to describe ourselves as a “later stage accelerator or scale-up program”. This means that if you are just completing your pre-clinical work, or you have just started your phase I or phase II clinical studies, or you are just waiting for regulatory approval or, again, you are already on the market and are looking to keep growing, you are definitely a great fit for this program. However, we are equally comfortable working with early stage companies that feel they could benefit from the work with an industrial partner.

Deloitte: the Deloitte Life Sciences & Health Care Global Network can count on over 13.000 dedicated people spread across 90+ Countries. Our clients include 8 of the 9 largest Health Care companies and 17 of the 18 largest Life Sciences companies. MSD Italy: MSD is the pharma company that invests the most in R&D (9,8 Billion USD), it generates over 40 Billion USD in revenues from over 190 proprietary drugs and operates in 140 Countries worldwide. Intesa Sanpaolo RBM Salute: Intesa Sanpaolo RBM Salute is the largest health insurer on the Italian market with well over 4 million clients including individuals and corporates. SCIENTIFIC HEALTHCARE PARTNERS Gruppo Villa Maria Care & Research: GVM Care & Research is one of the largest Italian healthcare groups covering everything from clinical research to well-being, to nutrition, to the biomedical industry. It can count on over 9.300 people across Italy, France, Albania, Poland, Russia and Ukraine. Humanitas: Humanitas Research Hospital, with several centers across Italy is one of the most advanced hospitals in Europe and, according to Harvard University, one the 4 most innovative hospitals worldwide. Santagostino: Santagostino is a young, dynamic and innovation-driven healthcare provider that in just 11 years has grown to having nearly 30 centers across Italy with 70+ specialties, delivering healthcare to nearly 500.000 people. Gruppo San Donato: Gruppo San Donato is the largest private Italian hospital group, with 56 centers across Italy, over 5.300 physicians and nearly 5 million patients treated every year. SCIENTIFIC RESEARCH PARTNERS Italian Institute of Technology: IIT is a prominent Italian research foundation for basic and applied research. It can count on over 1.700 people from 60+ Countries; it has generated 14.500 scientific publications and holds over 1000 patents. University of Milan: the University of Milan boasts nearly 230.000 scientific publications, 53 research centers and well over 50.000 students. IFOM: founded in 1998, IFOM is a non-profit cancer research institute with labs in Italy, India and China, focused on the study of cancer formation and development at molecular level, with a view to a rapid transfer of results from bench to bedside. INVESTOR PARTNERS Italian Angels for Growth: IAG is the largest Italian Business Angels association. Their track record includes a portfolio of 80+ funded startups with 200+ million Euros invested. Digital Magics: Digital Magics is a prominent Italian business incubator with 9 locations in Italy and London, an active portfolio of 62 startups that have raised well over 60 million euros. Panakès Partners: Panakès is a venture capital firm investing in Life Sciences early-stage startups and SMEs mainly across Europe and Israel. SUPPORTING PARTNER Life Science District: LSD is a young and dynamic startup and scaleup accelerator for biotech ventures. It can boast a broad international network of Life Sciences gurus, investors, pharma companies, healthcare institutions and startups.

If you have more questions please contact us at hello@healthbiotechaccelerator.io